Prestige Consumer Healthcare Inc. has announced impressive financial results for the second quarter of fiscal 2027, marking a significant revenue increase and a positive outlook for the company. The results, disclosed in a recent SEC filing, highlight the company's strong performance driven by its leading brands and recent acquisitions.

On November 5, 2026, Prestige Consumer Healthcare (NYSE: PBH) reported that its revenue for the second quarter reached $336.3 million, reflecting a 22.7% increase compared to the same period last year. The company also reported diluted earnings per share (EPS) of $0.53, with an adjusted diluted EPS of $1.13, up from $1.07 in the previous year.

“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right portfolio and LaCorium acquisitions that closed in June and July, respectively,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare. He noted that the company's portfolio performed as expected, with strong consumption growth across various channels, including eCommerce.

This strong performance has led Prestige to adjust its revenue guidance for the fiscal year, now estimating between $1,280 million and $1,290 million, and an adjusted diluted EPS range of $4.48 to $4.55.

Background

Prestige Consumer Healthcare Inc. is a prominent player in the pharmaceutical preparations industry, classified under SIC 2834. The company, which trades on the New York Stock Exchange under the ticker PBH, focuses on providing over-the-counter healthcare products. Prestige Consumer has undergone several transformations, including a name change from Prestige Brands Holdings, Inc. in 2004.

What the Filing Says

The SEC filing, accession number 0001295947-26-000055, details the financial results for the fiscal quarter and six months ending September 30, 2026. The filing includes a press release and an investor presentation that outlines the company's financial performance and future outlook.

Impact

The results of Prestige Consumer Healthcare's second quarter may impact various stakeholders, including investors, analysts, and competitors in the pharmaceutical preparations sector. The strong revenue growth and positive guidance adjustments may enhance investor confidence and influence market perceptions of the company's stability and growth potential.

What's Next

The filing does not specify what happens next, but the company is expected to continue its presentations to investors and analysts, utilizing the investor presentation materials disclosed in the filing.